目的 探讨迈之灵片联合卵磷脂络合碘片治疗中心性浆液性脉络膜视网膜病变的临床疗效。方法 选取2013年1月-2016年1月在咸阳市第一人民医院接受治疗的中心性浆液性脉络膜视网膜病变患者78例为研究对象，按照治疗方法的差别分成对照组和治疗组，每组各39例。对照组口服卵磷脂络合碘片，1片/次，3次/d。治疗组在对照组基础上口服迈之灵片，2片/次，3次/d。两组患者均治疗2个月。观察两组的临床疗效，比较两组患者的视力情况。结果 治疗后，对照组和治疗组的总有效率分别为79.49%、94.87%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者的视力情况均明显提高，同组治疗前后差异有统计学意义（P<0.05）；且治疗组这些观察指标的改善程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 迈之灵片联合卵磷脂络合碘片治疗中心性浆液性脉络膜视网膜病变具有较好的临床疗效，能改善视力，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Maizhiling Tablets combined with Iodized Lecithin Tablets in treatment of central serous chorioretinopathy. Methods Patients (78 cases) with central serous chorioretinopathy in the First People's Hospital of Xianyang City from January 2013 to January 2016 were enrolled in this study. According to the difference treatment plan, patients were divided into the control and treatment groups, and each group had 39 cases. Patients in the control group were po administered with Iodized Lecithin Tablets, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Maizhiling Tablets on the basis of the control group, 2 tablets/time, twice daily. After treatment, the clinical efficacies were evaluated, and the visual acuity in two groups was compared. Results After treatment, the clinical efficacies in the control and treatment groups were 79.49% and 94.87%, respectively, and there was difference between two groups (P<0.05). After treatment, the visual acuity in two groups was significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Maizhiling Tablets combined with Iodized Lecithin Tablets has clinical curative effect in treatment of central serous chorioretinopathy, and can improve visual acuity, which has a certain clinical application value.